

Review Letter

Receptor-phosphoinositidase C coupling

Multiple G-proteins?

William W.Y. Lo and John Hughes

Parke-Davis Research Unit, Addenbrookes Hospital Site, Hills Road, Cambridge CB2 2QB, England

Received 14 August 1987

Recent evidence has suggested that receptor-mediated phosphoinositide turnover, like that of the adenylate cyclase cAMP pathway, is regulated by guanine nucleotides. It is likely that one or more guanine nucleotide-binding proteins (G-proteins) couple calcium-mobilizing receptors to the activation of phosphoinositidase C. Recent studies utilizing various bacterial toxins have strongly suggested the presence of multiple G-proteins in the regulation of receptor-phosphoinositidase C coupling in a variety of cell types.

G-protein; Phosphoinositidase C; Phosphoinositide; Pertussis toxin; Cholera toxin; *ras* oncogene

In 1984, Berridge and Irvine [1] wrote that "...the well established role of GTP-binding proteins in controlling cAMP production may thus be extended to include the regulation of other transduction mechanisms such as inositol trisphosphate formation by calcium-mobilizing receptors...". Since then, a large number of reports have accumulated which strongly suggest a role for a GTP-binding protein (G-protein) in receptor-mediated phosphoinositidase C-activated polyphosphoinositide metabolism [2]. Although it is now clear that a G-protein is essential for phosphoinositidase C activation, unlike that responsible for adenylate cyclase activation the identity of this G-protein is still uncertain.

Bacterial toxins have proved to be useful tools to distinguish the G-proteins of the adenylate cyclase system. The toxins from *Vibrio cholerae* and *Bordetella pertussis* ADP-ribosylate G-proteins. While pertussis toxin ADP-ribosylates G_i and thus impairs the receptor-mediated inhibition of cyclase, cholera toxin ADP-ribosylates G_s which

leads to persistent stimulation of cyclase [3]. Using these two toxins as probes to identify the G-protein that regulates phosphoinositide response, it seems that there are at least three (or even more) putative G-proteins involved in receptor-phosphoinositidase C coupling (table 1).

The first, G_P is a substrate for neither pertussis toxin nor cholera toxin and is likely to be coupled to muscarinic receptors in astrocytoma cells [4] and cardiac myocytes [5]; angiotensin, vasopressin and α_1 -adrenergic receptors in rat liver membranes [6]; TRH receptors in GH₃ cells [7] and thrombin receptors in fibroblasts [8]. In addition, the GTP-binding protein encoded by *ras* (proto)oncogenes may also be involved in receptor-linked inositol phospholipid hydrolysis. When overexpressed, the p21 protein encoded by the N-*ras* protooncogene of normal, non-transformed cells greatly amplifies phosphoinositidase C activation to bombesin, vasopressin, bradykinin and platelet-derived growth factor (PDGF) [9]. (It is important to note that the analogy between *ras* gene products and other G-proteins only applies to the α -subunits of the latter. A *ras*-specific equivalent of the β/γ -subunits of other G-proteins has not been identified nor does p21 interact with β/γ -subunits of

Correspondence address: W.W.Y. Lo, Parke-Davis Research Unit, Addenbrookes Hospital Site, Hills Road, Cambridge CB2 2QB, England

Table 1
Possible G-proteins involved in receptor-phosphoinositidase C coupling
in some cell types

G-protein	Toxin substrate	Receptor	Cell type
G _P	—	muscarinic [4] angiotensin II, vasopressin [6] TRH [7]	astrocytoma cells liver membranes GH ₃ cells
G _o , G _i or G _o /G _i -like	pertussis toxin	f-Met-Leu-Phe [14–16] compound 48/80 [17] thrombin [19] bradykinin [20]	HL-60 cells PMN leukocytes neutrophils mast cells CCL39 cells F-11 cells
G _c	cholera toxin	T-cell antigen [22] CCK-8, muscarinic, bradykinin [25,26] secretin [24] vasopressin ^a	Jurkat cells Flow 9000 cells pancreatic acinar cells WRK-1 cells

^a Kirk, C.J. (personal communication)

other G-proteins [10].) Since p21 is a substrate of neither cholera toxin nor pertussis toxin [11], it is possible that p21 may represent the putative G_P protein. However, it must be emphasized that opposite effects on receptor-phosphoinositidase C coupling have been observed in some other cell systems when overexpressed with the *ras* gene(s). Benjamin et al. [12] showed that in NIH-3T3 cells transfected with the *ras* oncogene isolated from EJ human carcinoma (EJ-*ras*) there was a reduction of PDGF-stimulated phosphoinositidase C activity. Similarly, a loss of PDGF receptor-activated phosphoinositidase C activity was observed in NIH-3T3 cells transfected with the v-Ha-gene [13]. Additional evidence must be provided to explain these discrepancies and to establish the role of the *ras* gene product in receptor-mediated phosphoinositide metabolism.

In contrast, activation of phosphoinositidase C by chemotactic peptide in HL-60 cells [14], human polymorphonuclear leukocytes [15] and rabbit neutrophil [16], by compound 48/80 in mast cells [17], by α_1 -adrenergic agonists in adipocytes [18], by thrombin in hamster fibroblastic CCL39 cells [19] and by bradykinin in clonal F-11 dorsal root ganglion hybrid cells [20] is inhibited by pertussis

toxin pretreatment. These data suggest that the pertussis toxin substrate G_i, G_o or a G_i/G_o-like G-protein may be involved in the phosphoinositide response in some cell types. Indirect evidence from Snyder's laboratory showed that immunohistochemical localizations of G_o and protein kinase C correspond in many areas of the brain suggesting a potential role for G_o in the regulation of the phosphoinositide response [21]. Reconstitution experiments using purified G_o or G_i will provide valuable information to the above observations.

A novel cholera toxin-sensitive G-protein (G_c) might also be involved in mediating receptor-phosphoinositidase C coupling. Using the T-cell line Jurkat, Imboden and his colleagues reported that cholera toxin inhibits T-cell antigen receptor-mediated increases in both inositol trisphosphate level and cytoplasmic calcium concentration [22]. In the mouse macrophage cell line RAW264, cholera toxin has been shown to inhibit chemotaxis via a cAMP-independent mechanism, possibly through impairment of the PI response [23]. Moreover, secretin receptor-stimulated inositol trisphosphate formation in rat pancreatic acinar tissues was also inhibited by cholera toxin treatment [24]. In our laboratory, we found that

pretreatment of Flow 9000 cells (a human embryonic pituitary cell line) with cholera toxin (but not pertussis toxin) produces a dose-dependent inhibition of cholecystokinin, acetylcholine and bradykinin stimulation of inositol phosphate formation [25,26]. Cholera toxin treatment did not affect GTP analogue-induced inositol phosphate accumulation in permeabilized Flow 9000 cells but inhibited the GTP[S] potentiation of hormonal responses, indicating that the impairment is not at the GTP- or phosphoinositidase C-binding sites on G_c but influences the site responsible for receptor- G_c coupling. In WRK-1 mammary tumour cells, vasopressin-activated PIP_2 hydrolysis is mediated via a G-protein [27]. Pretreatment of WRK-1 cells with cholera toxin, but not with pertussis toxin, produced a dose-dependent inhibition on vasopressin-induced inositol phosphate accumulation (Kirk, C.J., University of Birmingham, personal communication). These results thus provide further evidence for the involvement of a novel cholera toxin-sensitive G-protein in inositol phospholipid signalling. In all of the above observations, the cholera toxin effects cannot be mimicked by cAMP-generating agents indicating that these effects are not a consequence of ADP-ribosylation of G_s .

Taken together, these findings indicate that at least three different G-proteins are responsible for regulating receptor-phosphoinositidase C coupling. Structural evidence similar to that achieved for the G-proteins coupling to adenylate cyclase [11] will be required to confirm these observations.

ACKNOWLEDGEMENTS

W.W.Y.L. is a Commonwealth Scholar and a Bye-Fellow at Downing College, Cambridge.

REFERENCES

- [1] Berridge, M.J. and Irvine, R.F. (1984) *Nature* 312, 315–321.
- [2] Taylor, C.W. and Merritt, J.E. (1986) *Trends Pharmacol. Sci.* 7, 238–242.
- [3] Gilman, A.G. (1986) *Trends Neurosci.* 9, 460–463.
- [4] Hepler, J.R. and Harden, T.K. (1986) *Biochem. J.* 239, 141–146.
- [5] Masters, S.B., Martin, M.W., Harden, T.K. and Brown, J.H. (1985) *Biochem. J.* 227, 933–937.
- [6] Lynch, C.J., Prpic, V., Blackmore, P.F. and Exton, J.H. (1986) *J. Pharm. Exp. Therap.* 29, 196–203.
- [7] Straub, R.E. and Gershengorn, M.C. (1986) *J. Biol. Chem.* 261, 2712–2717.
- [8] Murayama, T. and Ui, M. (1985) *J. Biol. Chem.* 260, 7226–7233.
- [9] Wakelam, M.J.O., Davies, S.A., Houslay, M.D., McKay, I., Marshall, C.J. and Hall, A. (1986) *Nature* 323, 173–176.
- [10] Broek, D., Samiy, N., Fasano, O., Fujijama, A., Tamanoi, F., Northup, J. and Wigler, M. (1985) *Cell* 41, 763–769.
- [11] Gilman, A.G. (1986) *Trends Neurosci.* 9, 460–463.
- [12] Benjamin, C.W., Tarpley, W.G. and Gorman, R.R. (1987) *Proc. Natl. Acad. Sci. USA* 84, 546–550.
- [13] Parries, G., Hoebel, R. and Racker, E. (1987) *Proc. Natl. Acad. Sci. USA* 84, 2648–2652.
- [14] Kikuchi, A., Kozawa, O., Kaibuchi, K., Katada, T., Ui, M. and Takai, Y. (1986) *J. Biol. Chem.* 261, 11558–11562.
- [15] Smith, C.D., Lane, B.C., Kusaka, I., Verghese, M.W. and Snyderman, R. (1985) *J. Biol. Chem.* 260, 5875–5878.
- [16] Volpi, M., Naccache, P.H., Molski, T.F.P., Shefcyk, J., Huang, C.-K., Marsh, M.L., Munoz, J., Becker, E.L. and Sha'afi, R.I. (1985) *Proc. Natl. Acad. Sci. USA* 82, 2708–2712.
- [17] Nakamura, T. and Ui, M. (1985) *J. Biol. Chem.* 260, 3584–3593.
- [18] Moreno, F.J., Mills, I., Garcia-Sainz, J.A. and Fain, J.N. (1983) *J. Biol. Chem.* 258, 10938–10943.
- [19] Paris, S. and Pouyssegur, J. (1986) *EMBO J.* 5, 55–60.
- [20] Francel, P.C., Millar, R.J. and Dawson, G. (1987) *J. Neurochem.* 48, 1632–1639.
- [21] Worley, P.F., Baraban, J.M., Van Dop, C., Neer, E.J. and Snyder, S.H. (1986) *Proc. Natl. Acad. Sci. USA* 83, 4561–4565.
- [22] Imboden, J.B., Shoback, D.M., Pattison, G. and Stobo, J.D. (1986) *Proc. Natl. Acad. Sci. USA* 83, 5673–5677.
- [23] Aksamit, R.R., Backlund, P.S. jr and Cantoni, G.L. (1985) *Proc. Natl. Acad. Sci. USA* 82, 7475–7479.
- [24] Trimble, E.R., Bruzzone, R., Biden, T.J., Meehan, C.J., Andrea, D. and Merrifield, R.B. (1987) *Proc. Natl. Acad. Sci. USA* 84, 3146–3150.
- [25] Lo, W.W.Y. and Hughes, J. (1987) *FEBS Lett.* 220, 327–331.
- [26] Lo, W.W.Y. and Hughes, J. (1987) *Biochem. Soc. Trans.* 15, 1153.
- [27] Guillon, G., Balestre, M.N., Mouillac, B. and Devilliers, G. (1986) *FEBS Lett.* 196, 155–159.